Brokerages Set MiMedx Group, Inc. (NASDAQ:MDXG) Target Price at $12.00

MiMedx Group, Inc. (NASDAQ:MDXG) has been given an average rating of “Buy” by the five ratings firms that are presently covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $12.00.

Separately, StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $9.16 on Friday. MiMedx Group has a one year low of $5.47 and a one year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company has a market cap of $1.35 billion, a price-to-earnings ratio of 16.65 and a beta of 1.98. The firm has a 50 day simple moving average of $7.64 and a 200 day simple moving average of $7.02.

Hedge Funds Weigh In On MiMedx Group

Large investors have recently modified their holdings of the business. SkyView Investment Advisors LLC increased its holdings in MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after purchasing an additional 3,000 shares during the period. Barclays PLC increased its stake in shares of MiMedx Group by 163.9% in the third quarter. Barclays PLC now owns 262,449 shares of the company’s stock valued at $1,550,000 after buying an additional 163,005 shares during the period. Orion Capital Management LLC raised its position in shares of MiMedx Group by 46.3% during the third quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock worth $69,000 after acquiring an additional 3,700 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of MiMedx Group by 1.6% in the third quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company’s stock worth $16,518,000 after acquiring an additional 44,254 shares during the period. Finally, Disciplined Growth Investors Inc. MN boosted its holdings in MiMedx Group by 0.8% in the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock valued at $2,100,000 after acquiring an additional 2,737 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.